INTRODUCTION
Non-steroidal anti-inflammatory drugs presently are the most widely used drugs in medicine and their annual sales in the world are more than 6 billion dollars. Presently, more than 100 NSAIDs have been tested clinically and more than 50 are there in the world market. Nearly 35 million people are taking them on daily basis and FDA has ranked them the most frequent cause of adverse drug reactions. 1 The spectrum of adverse reactions is broad. The most frequent problems are gastrointestinal, the most common being dyspepsia. Dyspepsia is a common symptom of gastrointestinal complications of NSAIDs use and is usually complained by about 10-12% of patients taking NSAIDs. Dyspepsia may lead to non-compliance with NSAID therapy in 5-15% of patients. 2 Persistent dyspepsia is one of the most frequent side effects of NSAIDs and with few exceptions; it can be an indicator of onset of future gastrointestinal toxicity. with many other gastrointestinal problems, the development of gastritis, gastric or duodenal ulceration, hemorrhage or perforation, and other events that may lead to hospitalization or death. They may have adverse effects in all parts of the gastrointestinal tract, not only the stomach or duodenum, but; the esophagus, small intestine and colon also may be affected. 3 Dyspeptic symptoms occur in up to 60% of patients taking NSAIDs and there is a poor correlation between symptoms and endoscopically proved lesions. Up to 50% of endoscopically confirmed ulcers associated with NSAIDs are asymptomatic.
Although endoscopic studies reveal that gastric or duodenal ulcers develop in 15-30% of patients who regularly take NSAIDs, the chief concern is clinically important gastro intestinal problems, such as bleeding, leading to anemia. It has been estimated that more than 1,00,000 patients are hospitalized and 16,500 die each year in the United states, as a result of NSAID related gastrointestinal events. 4 Since NSAIDs remain the single most commonly used class of therapeutic agents in medical practice today, the high prevalence of gastric erosions is a major public health concern and moreover, no drug in this class can safely be exonerated from gastrointestinal toxicity. NSAID induced gastric erosions and ulcers are indeed now identified as a serious problem of public health. Moreover, since over half of ulcers and bleeds will be silent, this problem has tended to be underrated and inadequately responded to. 5, 6 Estimates of the absolute risk vary from approximately two cases of NSAID induced serious upper gastrointestinal adverse effects per 10,000 person months of prescriptions to a seven fold increase in the risk of hospitalization in patients with rheumatoid arthritis. NSAIDs are the direct cause of 20-30% of all cases of complications of peptic ulcer disease. 7 Patients using NSAIDs are more than five times more likely to be hospitalized for treatment related gastrointestinal problems than non-users and mortality among patients hospitalized for gastrointestinal bleeding is 5-10%. These potential life-threatening events are all the more menacing because they mainly occur without antecedent gastrointestinal warning symptoms. 8 NSAIDs apparently produce gastro duodenal damage by two independent mechanisms, a direct local irritant effect and a systemic effect. Thus, enteric-coated tablets that do not release NSAID in the stomach produce less mucosal damage than normal preparations, although they still appear to be ulcerogenic (Hoftiezer et al; Jaszewski et al, Oddsson et al). Therefore, the potential risk of gastro-duodenal complications may be reduced by the use of short-term preoperative parenteral NSAID treatment compared with oral NSAID treatment, but not altogether eliminated. Even short-term NSAID treatment (3-7 days) in volunteers leads to endoscopically detectable superficial gastro-duodenal mucosal lesions, but not to a clinically significant risk of severe complications. Long-term treatment with NSAIDs, may lead to complications in the small and large intestine, including erosions and strictures (Aabakken; Rooney and Bjarnason). However, these complications have not been observed clinically during short-term treatment (less than one week). There seems to be no clinically important differences in serious gastrointestinal side effects between various NSAIDs when used for short-term treatment. 9 Previous studies report, that selective COX-2 inhibitors are safer when compared to non-selective cyclooxygenase inhibitors, regarding their adverse effects on the gastrointestinal tract. But, recent studies reveal, that gastrointestinal safety of these selective COX-2 inhibitors is not much better than that of conventional NSAIDs.
It is therefore, important to assess the gastrointestinal safety and side effects of newer COX-2 inhibitors. In view of the larger usage of this new group of drugs, the study has been taken up to report, whether selective COX-2 inhibitors have got any advantages over conventional NSAIDs or not, in regard to their gastrointestinal toxicity, especially when used for a routine short-term treatment; by analyzing few nonselective and selective groups of NSAIDs.
Aims and objectives
Aims and objectives of the study were to compare the gastric toxicity of non-selective NSAIDs with that of selective COX-2 inhibitors.
METHODS
An interventional and prospective study was taken up with the approval of institutional ethical committee. All patients included in our study gave informed consent for their participation and the study was done at Mahatma Gandhi Memorial Hospital, Warangal, India. Patients were divided into eight groups, fifteen patients of each. Each group was given one of the NSAIDs from the eight drugs those were selected for the study. In the selected group, prior to the administration of drug, Hb% estimation was done in all the patients, by using Cyan methhemoglobin method & the values were recorded and tabulated.
The patients were advised to take the concerned NSAID, for a period of fifteen days, and they were not put on any antacid or H2-blocker or proton pump inhibitor. All the out patients were briefed, of the common toxicity of the concerned NSAID and they were advised to inform us soon after the onset of symptoms like nausea, vomiting, diarrhea, epigastric pain, heartburn, dyspepsia, facial and pedal edema, headache and tinnitus. Whenever the patient reported an adverse effect, he or she was advised to stop the treatment and it was taken as the primary end point of our study, for that particular patient. After the completion of treatment, Hb% estimation was repeated again and the values were recorded, tabulated and both the pre & post treatment values were subjected to statistical analysis with the help of paired't' test.
The following side effects were noted down, if any, during the treatment period, in a proper case sheet proforma and tabulated, separately for each drug.
Gastric toxicity parameters
 Nausea  Vomiting  Abdominal pain  Heartburn  Dyspepsia  Hematemesis  Constipation  Diarrhea
RESULTS
In our present short-term study, non-selective NSAIDs like ibuprofen and diclofenac were shown to be associated with risk of gastric toxicity, diclofenac being on the higher side; whereas, among the selective COX-2 inhibitors, nimesulide and celecoxib were shown to be associated with higher gastric toxicity and meloxicam, rofecoxib & valdecoxib, little on lesser side. 
DISCUSSION

Effect on gastrointestinal system
In the present study, paracetamol proved to be extremely safe compared to other NSAIDs. 2 Ibuprofen showed little more, but not very bad gastric toxicity potential. This may be due to the fact that we use small doses of ibuprofen for its anti-inflammatory effect. [10] [11] [12] But, high dose ibuprofen was thought to be associated with increased gastric toxicity compared to other NSAIDs. [10] [11] [12] [13] Diclofenac was associated with gastric toxicity, higher than that of ibuprofen in our present study. The incidence of serious gastrointestinal adverse effects did not differ between diclofenac and the COX-2-selective inhibitor, celecoxib (Juni et al, 2002) , likely because diclofenac exhibits a degree of COX-2 selectivity that is similar to that of celecoxib. Nimesulide, also showed much gastric toxicity similar to that of non-selective NSAIDs; even though it has some COX-1 sparing action. This may be due to the fact that it is not a purely COX-2 selective inhibitor. 1, 14, 15 Meloxicam has also been shown to have gastric toxicity, but, to a lesser extent than that of nimesulide.
14 CLASS and VIGOR trials showed a lower relative risk of serious gastro intestinal complications with selective COX-2 inhibitors. [16] [17] [18] [19] [20] Furthermore, subsequent analysis of CLASS study, highlighted by FDA found that the benefits shown in six months analysis were not continued to the twelve months end point of study, placing doubt on the clinical significance of any gastro intestinal safety benefits from chronic use of selective COX-2 inhibitors over traditional NSAIDs. 21 In the present study, celecoxib, a selective COX-2 inhibitor showed gastro intestinal toxicity similar to that of non-selective NSAIDs. 15, 22 FDA also found that, for upper gastro intestinal safety, there does not appear to be any meaningful advantage for celecoxib. 22 But, the rate of gastro intestinal complication is less with rofecoxib and valdecoxib in the present short-term study.
In the present study, diclofenac and meloxicam have shown significant change in the 'p' value, in the assessment of Hb% change both before and after treatment, showing that there must have been gastric bleeding erosions which must have given rise to such changes and thus to anemia, without any alarming symptoms.
CONCLUSION
Inhibition of COX-1 by NSAIDs is linked to gastro intestinal toxicity. Those drugs, which selectively inhibit COX-2, were thought to have less gastro intestinal toxicity. But, they still had sufficient COX-1 inhibition to cause potent inhibitory effects on gastric PGE2 synthesis and thus are responsible for gastric toxicity, similar to that of non-selective NSAIDs. Hence, all currently used NSAIDs, including both conventional and selective COX-2 inhibitors do have inherent gastric toxicity, at therapeutic concentrations. Further long-term studies are required to assess the clinical safety of these selective COX-2 inhibitors.
